{"id":"NCT00070941","sponsor":"NYU Langone Health","briefTitle":"SAM-e for the Treatment of Depression in Patients With Parkinson's Disease","officialTitle":"SAM-e Treatment of Depression in Parkinson's Disease.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2003-07","primaryCompletion":"2010-06","completion":"2010-10","firstPosted":"2003-10-13","resultsPosted":"2016-07-13","lastUpdate":"2016-07-13"},"enrollment":29,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease","Depression"],"interventions":[{"type":"DRUG","name":"SAM-e","otherNames":["1 Experimental"]},{"type":"DRUG","name":"oral escitalopram","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"SAM-e","type":"EXPERIMENTAL"},{"label":"Escitalopram","type":"ACTIVE_COMPARATOR"},{"label":"Placebo Comparator","type":"PLACEBO_COMPARATOR"}],"summary":"This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).","primaryOutcome":{"measure":"Change in Hamilton Depression Scale","timeFrame":"12 weeks","effectByArm":[{"arm":"SAM-e","deltaMin":17,"sd":4.8},{"arm":"Escitalopram","deltaMin":17.5,"sd":5.4},{"arm":"Placebo Comparator","deltaMin":20.7,"sd":3.2}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":12},"commonTop":["INSOMNIA","NAUSEA","CONSTIPATION","MOUTH DRY","ANOREXIA"]}}